Abstract: Novel tools and techniques are provided for implementing real-time fault management or real-time fault management system (“RFM”). In various embodiments, RFM may receive alerts from or associated with network devices (e.g., layer 2, 3, and/or 4 devices, or the like) that are disposed in a plurality of disparate networks that may utilize different alert management protocols and/or different fault management protocols. RFM may collect, enrich, normalize, aggregate, and display the alerts in a user interface to facilitate addressing of the alerts by a user. To enable continuous and real-time functionality, RFM may be implemented in a plurality of siloed platforms in a primary data center, with processing of alerts being load balanced across the siloed platforms, with mirrored group of siloed platforms in a secondary data center located geographically distant from the primary data center and configured to be on “hot standby” and to completely take over RFM processing operations.

Abstract: Provided herein are scalable methods of processing wet-spun fiber comprising recombinant spider silk polypeptides to generate a three-dimensional crystalline lattice of beta-sheet structures in the fiber.

Abstract: Provided herein are scalable methods of processing wet-spun fiber comprising recombinant spider silk polypeptides to generate a three-dimensional crystalline lattice of beta-sheet structures in the fiber.

Abstract: Provided herein are scalable methods of spinning fiber comprising bi-constituent blends of cellulose and recombinant spider silk polypeptides. Also provided are compositions comprising blended fibers of cellulose and recombinant spider silk polypeptides.

Abstract: Provided herein are scalable methods of generating a recombinant silk polypeptide with a coefficient of friction sufficient to form mechanical interactions with other fibers.

Abstract: Provided herein are scalable methods of processing wet-spun fiber comprising recombinant spider silk polypeptides to generate a three-dimensional crystalline lattice of beta-sheet structures in the fiber.

Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.

Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.

Abstract: This invention relates to certain dendrimer compounds. In particular, this invention relates to novel dendrimer compounds that can be elaborated to give increasingly large and complex compounds. These elaborated compounds can be attached to, or can encapsulate within, active agent(s) so as to beneficially modify the characteristics of that active agent. Alternatively, the elaborated compounds can themselves be beneficially modified into therapeutic agents by the attachment of inactive agents.

Abstract: This invention relates to certain dendrimer compounds. In particular, this invention relates to novel dendrimer compounds that can be elaborated to give increasingly large and complex compounds. These elaborated compounds can be attached to, or can encapsulate within, active agent(s) so as to beneficially modify the characteristics of that active agent. Alternatively, the elaborated compounds can themselves be beneficially modified into therapeutic agents by the attachment of inactive agents.

Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.

Abstract: This invention relates to certain dendrimer compounds. In particular, this invention relates to novel dendrimer compounds that can be elaborated to give increasingly large and complex compounds. These elaborated compounds can be attached to, or can encapsulate within, active agent(s) so as to beneficially modify the characteristics of that active agent. Alternatively, the elaborated compounds can themselves be beneficially modified into therapeutic agents by the attachment of inactive agents.

Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.

Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.

Abstract: A method for detecting death process of a cell or tissue of a living subject. In one embodiment, the method includes the steps of illuminating the cell or tissue of the living subject with a coherent light, collecting fluorescent light returned from the illuminated cell or tissue of the living subject, identifying a NAD(P)H peak of a spectrum of the collected fluorescent light with a wavelength, ?peak, and obtaining the intensity of the NAD(P)H peak of the spectrum of the collected fluorescent light substantially corresponding to the wavelength ?peak. These steps are repeated at sequential stages until the intensity of the NAD(P)H peak of the spectrum at a current stage is less than the intensity of the NAD(P)H peak of the spectrum at an earlier stage immediately prior to the current stage so as to detect death process of the cell of the living subject at the current stage using the intensity of the NAD(P)H peak of the spectrum.

Abstract: A method for differentiating malignant in vivo liver tissues from normal in vivo liver tissues of a living subject includes the steps of: (a) illuminating a first area and a second area of in vivo liver tissues of the living subject with a first excitation light, (b) measuring an intensity of fluorescent light emitted from each of the first area and the second area of in vivo liver tissues in response to the first excitation light as a function of wavelength so as to obtain a first and a second fluorescent spectra, respectively, (c) illuminating the first area and the second area of in vivo liver tissues with a second excitation light, (d) measuring an intensity of diffuse light reflected by each of the first area and the second area of in vivo liver tissues in response to the second excitation light as a function of wavelength so as to obtain a first and a second diffused reflectance spectra, respectively, and (e) identifying one of the first area and the second area of in vivo liver tissues as malignant liv

Abstract: A method for detecting death process of a cell or tissue of a living subject. In one embodiment, the method includes the steps of illuminating the cell or tissue of the living subject with a coherent light, collecting fluorescent light returned from the illuminated cell or tissue of the living subject, identifying a NAD(P)H peak of a spectrum of the collected fluorescent light with a wavelength, ?peak, and obtaining the intensity of the NAD(P)H peak of the spectrum of the collected fluorescent light substantially corresponding to the wavelength ?peak. These steps are repeated at sequential stages until the intensity of the NAD(P)H peak of the spectrum at a current stage is less than the intensity of the NAD(P)H peak of the spectrum at an earlier stage immediately prior to the current stage so as to detect death process of the cell of the living subject at the current stage using the intensity of the NAD(P)H peak of the spectrum.